Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Subject who can understand and are able to provide informed consent. * Subject with moderate to severe COPD with normal cardiac, liver and renal function * Subject must have a post-bronchodilator FEV1/FVC ratio of less than 0.7 * Subject must have a post-bronchodilator FEV1 percent predicted value \<50% * Subject must have a RV/TLC ratio of \> 40% * Subject must be either a non-smoker or an ex-smoker, with a cigarette smoking history of ≥ 10 packs per year. * Subject must have abstained from nicotine products for at least six months prior to enrollment in the study. * Subject must be available for all specified assessments at the study site through the completion of the study. * Subject must have oxyhemoglobin saturation on room air at rest equal or greater than 88% without oxygen * Subject must be reasonably able to return for multiple follow-up visits. * Adequate venous access * For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. * Any male subject must agree to use contraceptives and not donate sperm during the study. Exclusion Criteria: * Subject with clinically significant illness with manifestations of significant organ dysfunction which in the judgment of the PI or co-investigator would render the study subject unlikely to tolerate the infusion or complete the study * Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion. * Subject has been diagnosed with a pulmonary disease other than COPD (e.g. asthma, pulmonary, fibrosis, sarcoidosis, pulmonary hypertension, bronchiolitis, interstitial lung disease) * Subject has been diagnosed with α1-Antitrypsin deficiency * Subject has a body mass index greater than 42 kg/m2 * Subject has or had an active infection requiring systemic antibiotics within 12 weeks on enrollment in the study * Subject has or had exacerbation of COPD requiring hospitalization within 12 weeks of enrollment in the study. * Subject has initiated pulmonary rehabilitation within 12 weeks of enrollment in the study * Subject uses or used prednisone (or equivalent dose of another corticosteroid) within 12 weeks of enrollment in the study * Subject has evidence or history of malignancy * Subject has evidence or history of autoimmune disorders independent of COPD * Subject is pregnant or breast-feeding * Subject with pulmonary lobectomy or lung volume reduction surgery or lung transplantation. Subject with clinically significant bronchiectasis. * Subject received an experimental therapy (drug or biologic) for any indication within 12 months of the study enrollment. * Subject is unable to complete all the testing required for the study * Subject who is on immunosuppressive medications. * Subject who is unwilling to stop taking prescription or over the counter pain medication for 7 days prior to any visit. * Subject with a history of bleeding disorders, anticoagulation therapy that cannot be stopped as prior to infusion. * Active listing (or expected future listing) for transplant of any organ. * Be a solid organ transplant recipient. This does not include prior cell-based therapy (\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection. * History of drug abuse (illegal "street" drugs) except noninhalation use of marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs withinthe past 24 months. Use of inhalation marijuana will be an exclusion criterion. * Subject with untreated HIV infection. However, patients can be enrolled if they have been treated for HIV and test negative for HIV viral load but still test positive for antibodies.